Business Context and Reporting Period
Company: Damora Therapeutics, Inc. (formerly Galecto, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Damora is a preclinical-stage biopharmaceutical company focused on developing therapies for hematologic disorders, specifically myeloproliferative neoplasms (MPNs). The company's strategy centers on a portfolio of anti-mutCALR product candidates (DMR-001, DMR-002, DMR-003) licensed from Paragon Therapeutics, Inc. In November 2025, the company completed an Asset Acquisition of "Pre-Acquisition Damora" to secure these rights and simultaneously raised capital through a PIPE transaction. The company changed its name from Galecto, Inc. to Damora Therapeutics, Inc. effective March 10, 2026.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Revenue | $0.0 | $0.0 |
| Net Loss | $(209.8) | $(21.4) |
| Total Operating Expenses | $210.9 | $22.3 |
| Research & Development (R&D) | $26.9 | $6.4 |
| Acquired In-Process R&D (AIPR&D) | $174.3 | $4.4 |
| General & Administrative (G&A) | $9.7 | $10.5 |
| Cash and Cash Equivalents (Year End) | $257.6 | $14.2 |
| Accumulated Deficit | $(487.4) | $(277.5) |
| Net Cash Used in Operating Activities | $(6.7) | $(18.6) |
| Net Cash Provided by Financing Activities | $266.8 | $0.0 |
Note: The 2025 net loss includes a one-time non-cash charge of $174.3 million for Acquired In-Process R&D related to the Asset Acquisition.
Material Changes vs. Prior Period
- Asset Acquisition: In November 2025, the company acquired Pre-Acquisition Damora, resulting in a $174.3 million expense for acquired in-process R&D. This transaction shifted the company's focus entirely to the mutCALR portfolio (DMR-001, DMR-002, DMR-003) and led to the deprioritization of legacy assets (GB3226, GB1211, GB2064).
- Capital Raise: The company raised approximately $285 million in a PIPE transaction in November 2025 and an additional $297.3 million in a public offering in February 2026 (subsequent to year-end). This significantly improved liquidity from $14.2 million in 2024 to $257.6 million in 2025.
- Expense Structure: R&D expenses increased by 320% year-over-year, driven primarily by the Paramora Warrant expense ($9.4 million) and increased preclinical/CMC activities. G&A expenses decreased slightly by 8% due to reduced stock-based compensation.
- Corporate Structure: The company rebranded from Galecto, Inc. to Damora Therapeutics, Inc. and authorized an increase in common stock shares from 300 million to 500 million.
Guidance, Outlook, and Risks
Outlook and Milestones
- DMR-001: The lead product candidate targeting mutCALR. The company intends to file an IND/CTA in mid-2026 and initiate a Phase 1 trial in Essential Thrombocythemia (ET) and Myelofibrosis (MF) patients. Proof-of-concept readouts are expected beginning mid-2027.
- DMR-002 & DMR-003: IND/CTA filings are targeted for the second half of 2026 and 2027, respectively.
- Liquidity: Management believes existing cash of $257.6 million (as of Dec 31, 2025) is sufficient to fund operations into Phase 3 development of DMR-001.
Key Risks and Contingencies
- Preclinical Stage: The company has no products approved for commercial sale and has never generated product revenue. All product candidates are in preclinical stages.
- Capital Requirements: Substantial additional capital will be required to fund clinical trials and commercialization. Failure to raise capital could force delays or elimination of programs.
- Third-Party Reliance: The company relies heavily on Paragon Therapeutics for discovery and development under the Paragon Option Agreement. Termination of this agreement could halt development.
- Regulatory Uncertainty: Regulatory approval processes are lengthy and unpredictable. The company faces risks related to FDA and foreign regulatory authorities.
- Intellectual Property: The IP portfolio is at an early stage. The company does not currently own or license any issued patents for its product candidates; Paragon controls prosecution.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $257.6 million cash balance against the projected costs of advancing DMR-001 to Phase 3 and initiating Phase 1 trials for DMR-002/003.
- Paragon Agreement Terms: Review the specific milestone payments (up to $22.0 million) and royalty obligations (low to mid-single-digit) owed to Paragon upon successful development.
- Asset Acquisition Accounting: Confirm the treatment of the $174.3 million AIPR&D charge as a non-cash expense and its impact on the accumulated deficit.
- Preferred Stock Conversion: Monitor the conversion of Series B and Series C Preferred Stock into common stock, which impacts dilution and voting control.
- Preclinical Data Validation: Assess the robustness of the preclinical data claiming DMR-001 has 10-fold higher potency on Type 2 mutCALR and a 5-fold longer half-life compared to reference antibodies.